Beginning May 5, 2018, submitters MUST use eCTD for commercial IND
submissions. Non-commercial IND submissions (including investigator-sponsored
INDs and expanded access INDs) are exempt.
After these deadlines, paper submissions or electronic submissions that are NOT in
eCTD format will NOT be filed or received unless exempt from the requirement. There
are no waivers to the eCTD format.
signatures to enable automated processing of the submission. Fillable forms are fillable
on the computer, which makes it easier to process them electronically. Non-fillable forms
and scanned images of FDA forms will NOT be accepted.
How to Submit in eCTD Format: Resources to help you prepare and submit applications in eCTD format to CDER include:
The eCTD website contains relevant guidances and eCTD technical specifications, along
with a step-by-step guide to setting up an Electronic Submissions Gateway account and an
Study Data Standards provide a consistent general framework for organizing study
data, including templates for datasets, standard names for variables, and standard ways
of doing calculations with common variables. Data standards facilitate application reviews
and bring uniformity to assessments of drug safety and efficacy. Standardized data at all
levels of the drug lifecycle will enable researchers to better capture data and answer new
questions about medicines and health.
is a spreadsheet that provides a listing of supported and/or required standards, their uses,
the date FDA will begin (or has begun) to support a particular standard and the date support
ends (or will end), the date the requirement to use a particular standard will begin (or has begun)
and the date such requirement ends (or will end), and other pertinent information.
recommendations, and general considerations on how to submit standardized study data
using FDA-supported data standards located in the FDA Data Standards Catalog. It is
intended to complement and promote interactions between sponsors and FDA review
divisions. Sponsors and applicants must submit study data electronically for both clinical
and nonclinical studies.
Deadlines: Sponsors submitting studies to CDER or CBER that start after December 17, 2016
must use the data standards listed in the FDA Data Standards Catalog for:
- NDAs, ANDAs, BLAs
- All subsequent submissions to these types of applications, including amendments, supplements, and reports, even if the original submission was filed before the requirements went into effect.
The requirement for commercial INDs (for products that are intended to be distributed
commercially) starts after December 17, 2017. Data from studies starting before December 17, 2016,
need not be converted to comply with the standards. Non-commercial IND submissions
(including investigator-sponsored INDs and expanded access INDs) are exempt.
The FDA may refuse to file NDAs and BLAs, or refuse to receive ANDAs if an electronic
submission that contains study data does not conform to the required standards specified
in the FDA Data Standards Catalog.
Data Standards Catalog, guidance documents, and technical specifications. Exemptions are
We strongly encourage sponsors to plan for the implementation of the eCTD standard format now,
and to consider the use of data standards for the submission of applications as early as possible in
the product development lifecycle, so that data standards are accounted for in the design, conduct,
and analysis of studies.
Cheers,
Renu Lal, Pharm.D.
CDER Small Business and Industry Assistance
|
No hay comentarios:
Publicar un comentario